Frontier mental health research: psychedelics & drug studies

Key findings

• Small clinical trials have reported that LSD can reduce anxiety symptoms in some people, including those with serious illnesses like cancer. ^{15068 15055 15135}
• In most studies the drug was given together with psychotherapy and lots of preparation. Researchers treat the drug and the therapy as one combined treatment. ^{15063 15065 15085}
• The overall evidence is still limited. Many trials are small, methods vary a lot, and no psychedelic medicine is officially approved for anxiety yet. ^{15078 15068 15085}
• When LSD and other psychedelics are used in controlled clinical studies, safety profiles have generally been acceptable and side effects were usually short and mild to moderate. But some psychedelics carry serious risks in other settings, so careful medical oversight is important. ^{15135 15055 15085}
• Scientists think LSD acts on serotonin receptors and can make brain circuits more flexible (called neuroplasticity). This change in brain wiring is a leading idea for how it might reduce rigid patterns of worry. ^{15135 15050 15091}
• Biological markers are unclear: pooled studies did not find consistent rises in blood levels of BDNF (a protein linked to brain growth) after so‑called psychoplastogen drugs, which includes some psychedelics. ¹⁵¹²⁹
• People who took part in psychedelic treatments often describe gaining insights, feeling more connected, or having shifted self‑views. These reported experiences show how non‑drug factors matter for outcomes. ^{15092 15063}
• There are important gaps. Most trial participants have been White, so results may not apply to many groups. We also need larger and longer trials to learn about who benefits, the best dose and setting, and long‑term safety. ^{15095 15078 15068}